p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D053148:Caspase 3; D020169:Caspases / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000187:drug effects*; D050759:Cyclin-Dependent Kinase Inhibitor p21; D050761:Cyclin-Dependent Kinase Inhibitor p57; D016213:Cyclins / Q000187:drug effects; D004164:Diphosphonates / Q000494:pharmacology*; D004789:Enzyme Activation / Q000187:drug effects; D005434:Flow Cytometry; D045325:HCT116 Cells; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D020287:In Situ Nick-End Labeling; D009584:Nitrogen; D009687:Nuclear Proteins / Q000187:drug effects; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016159:Tumor Suppressor Protein p53 / Q000187:drug effects*; D000077211:Zoledronic Acid
D000970:Antineoplastic Agents; C493956:CDKN1A protein, human; C493964:CDKN1C protein, human; D018797:Cell Cycle Proteins; D050759:Cyclin-Dependent Kinase Inhibitor p21; D050761:Cyclin-Dependent Kinase Inhibitor p57; D016213:Cyclins; D004164:Diphosphonates; D007093:Imidazoles; D009687:Nuclear Proteins; D016159:Tumor Suppressor Protein p53; D000077211:Zoledronic Acid; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases; D009584:Nitrogen